drugset / Trial / NCT05057689

Safety & Efficacy of Intranasal Dexmedetomidine, Fentanyl & Midazolam in the Pediatric Emergency Room

NCT05057689

Phase 2 Withdrawn Nationwide Children's Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The hypothesis is that intranasal dexmedetomidine will provide significantly more effective analgesia and anxiolysis for subjects undergoing a simple laceration repair when compared to either intranasal fentanyl or intranasal midazolam. Additional hypotheses include that there will be 1) no significant increase in adverse effects between drugs and 2) significantly higher satisfaction rates for both subject experience and ease of laceration repair based on structured, proceduralist feedback.

Timeline

Start
2025-09
Primary completion
2025-10
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 4 ug/kg Intranasal
Subject Fentanyl Other / unclassified 2 ug/kg Intranasal
Subject Midazolam Small molecule 0.3 mg/kg Intranasal